+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

LAMEA Uveitis Treatment Market, by Drug Class, by Disease Type, by Distribution Channel, by Country, Industry Analysis and Forecast, 2019 - 2025

  • ID: 5017806
  • Report
  • March 2020
  • Region: Middle East, Africa
  • 90 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Amgen, Inc.
  • Enzo Biochem, Inc.
  • Novartis AG
  • TopiVert Ltd.
  • MORE
The Latin America, Middle East and Africa Uveitis Treatment Market is expected to witness market growth of 6.5% CAGR during the forecast period (2019-2025).

For the treatment of infectious uveitis, certain medications have advantages over others. Topical and systemic treatments are often used in the treatment of ocular infection, but the treatment route may be limited by penetration, concentration, and duration. The advent of antimicrobial intravitreal therapy has furthered the treatment of intraocular infections. With limited systemic absorption, being able to overcome blood-ocular barriers allows for large concentrations of drugs to be administered directly to the posterior section. Nevertheless, because the difference between the therapeutic and toxic doses of certain antimicrobial drugs falls within a small range of concentration, intravitreal therapy can be associated with risks of ocular toxicity.

Intermediate uveitis is a vitreous and peripheral retina-localized type of uveitis. Primary inflammatory sites include the vitreous which includes other entities such as pars planitis, posterior cyclitis, and hyalitis. Intermediate uveitis may be either an isolated eye disease or related to the development of a systemic condition such as multiple sclerosis or sarcoidosis. As such, the first manifestation of a systemic disorder may be intermediate uveitis. Infectious causes of intermediate uveitis include infection with the Epstein-Barr virus, Lyme disease, HTLV-1 virus, cat scratch disease, and hepatitis C.

Permanent vision loss is most often observed in patients suffering from chronic cystoid macular edema (CME). While present, every attempt must be made to eliminate CME. Retinal detachment, glaucoma, band keratopathy, cataract, vitreous hemorrhage, epiretinal membrane, and choroidal neovascularization are also less common causes of visual impairment.

Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.

Scope of the Study

Market Segmentation:

By Drug Class
  • Anti-inflammatory
  • Immunotherapy & Targeted Therapies
  • Antimicrobial Drugs
  • Other Drug Class
By Disease Type
  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online stores
By Country
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Enzo Biochem, Inc.
  • Amgen, Inc.
  • Bausch Health Companies, Inc.
  • Clearside Biomedical, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • TopiVert Ltd.
  • Novartis AG
Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Amgen, Inc.
  • Enzo Biochem, Inc.
  • Novartis AG
  • TopiVert Ltd.
  • MORE
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Uveitis Treatment Market, by Drug Class
1.4.2 LAMEA Uveitis Treatment Market, by Disease Type
1.4.3 LAMEA Uveitis Treatment Market, by Distribution Channel
1.4.4 LAMEA Uveitis Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. LAMEA Uveitis Treatment Market by Drug Class
3.1 LAMEA Anti-inflammatory Market by Country
3.2 LAMEA Immunotherapy & Targeted Therapies Market by Country
3.3 LAMEA Antimicrobial Drugs Market by Country
3.4 LAMEA Other Drug Class Market by Country

Chapter 4. LAMEA Uveitis Treatment Market by Disease Type
4.1 LAMEA Anterior Uveitis Market by Country
4.2 LAMEA Posterior Uveitis Market by Country
4.3 LAMEA Intermediate Uveitis Market by Country
4.4 LAMEA Other Diseases Market by Country

Chapter 5. LAMEA Uveitis Treatment Market by Distribution Channel
5.1 LAMEA Hospital Pharmacies Market by Country
5.2 LAMEA Retail Pharmacies Market by Country
5.3 LAMEA Online stores Market by Country

Chapter 6. LAMEA Uveitis Treatment Market by Country
6.1 Brazil Uveitis Treatment Market
6.1.1 Brazil Uveitis Treatment Market by Drug Class
6.1.2 Brazil Uveitis Treatment Market by Disease Type
6.1.3 Brazil Uveitis Treatment Market by Distribution Channel
6.2 Argentina Uveitis Treatment Market
6.2.1 Argentina Uveitis Treatment Market by Drug Class
6.2.2 Argentina Uveitis Treatment Market by Disease Type
6.2.3 Argentina Uveitis Treatment Market by Distribution Channel
6.3 UAE Uveitis Treatment Market
6.3.1 UAE Uveitis Treatment Market by Drug Class
6.3.2 UAE Uveitis Treatment Market by Disease Type
6.3.3 UAE Uveitis Treatment Market by Distribution Channel
6.4 Saudi Arabia Uveitis Treatment Market
6.4.1 Saudi Arabia Uveitis Treatment Market by Drug Class
6.4.2 Saudi Arabia Uveitis Treatment Market by Disease Type
6.4.3 Saudi Arabia Uveitis Treatment Market by Distribution Channel
6.5 South Africa Uveitis Treatment Market
6.5.1 South Africa Uveitis Treatment Market by Drug Class
6.5.2 South Africa Uveitis Treatment Market by Disease Type
6.5.3 South Africa Uveitis Treatment Market by Distribution Channel
6.6 Nigeria Uveitis Treatment Market
6.6.1 Nigeria Uveitis Treatment Market by Drug Class
6.6.2 Nigeria Uveitis Treatment Market by Disease Type
6.6.3 Nigeria Uveitis Treatment Market by Distribution Channel
6.7 Rest of LAMEA Uveitis Treatment Market
6.7.1 Rest of LAMEA Uveitis Treatment Market by Drug Class
6.7.2 Rest of LAMEA Uveitis Treatment Market by Disease Type
6.7.3 Rest of LAMEA Uveitis Treatment Market by Distribution Channel

Chapter 7. Company Profiles
7.1 AbbVie, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals:
7.2 Alimera Sciences, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.1 Recent strategies and developments:
7.2.1.1 Product Launches and Product Expansions:
7.3 Enzo Biochem, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Amgen, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Research & Development Expense
7.4.4 Recent strategies and developments:
7.4.4.1 Product Launches and Product Expansions:
7.4.4.2 Partnerships, Collaborations, and Agreements:
7.5 Bausch Health Companies, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.6 Clearside Biomedical, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Research & Development Expense
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 EyePoint Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product Launches and Product Expansions:
7.7.5.2 Acquisition and Mergers:
7.8 Santen Pharmaceutical Co., Ltd.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Topivert Ltd.
7.9.1 Company Overview
7.1 Novartis AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Recent strategies and developments:
7.10.4.1 Acquisition and Mergers:
7.10.4.2 Approvals:
7.10.5 Research & Development Expense
Note: Product cover images may vary from those shown
  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Enzo Biochem, Inc.
  • Amgen, Inc.
  • Bausch Health Companies, Inc.
  • Clearside Biomedical, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • TopiVert Ltd.
  • Novartis AG
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll